<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343395">
  <stage>Registered</stage>
  <submitdate>25/08/2011</submitdate>
  <approvaldate>29/08/2011</approvaldate>
  <actrnumber>ACTRN12611000920998</actrnumber>
  <trial_identification>
    <studytitle>A study of Abalone Haemocyanin for cold sores</studytitle>
    <scientifictitle>A Randomised, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate Safety and Efficacy of Topical Abalone Haemocyanin Once Daily for the Treatment of Herpes Labialis in Immunocompetent Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MBA-001-010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Herpes Labialis (cold sores)</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Abalone Haemocyanin (AH) 50mg applied topically once daily for 5 days within 6 hours of profromal symptom.</interventions>
    <comparator>Placebo solution applied topically</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective is to evaluate the duration of cold sore episodes in subjects treated with AH as compared with placebo.</outcome>
      <timepoint>From the date and time of prodromal symptom onset until the date and time the subject self-assessed the lesion was healed.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the efficacy of AH in preventing or blocking cold sore lesion development. This will be assessed by a subject diary recording of progression and duration of cold sore development. Also by Investigator clinical assessment.</outcome>
      <timepoint>From the date and time of prodromal symptom onset until the date and time the subject self-assessed the lesion was healed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety and tolerability of topical AH 50mg administered once daily for 5 days. This will be assessed by recording of adverse events, laboratory tests (haematology, biochemistry and urinalysis) and other clinical assessments (physical exam, vital signs and ECG).</outcome>
      <timepoint>From the date and time of prodromal symptom onset until the date and time the subject self-assessed the lesion was healed.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or female with history of recurrent cold sores and have experienced at least three episodes in the previous 12 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any significant unstable medical condition, allergic reaction or sensitivity to haemocyanin from any source, or a food allergy to seafood or shellfish.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible subjects will be randomised (1:1 ratio) to receive either active abalone haemocyanin or placebo. Allocation will be concealed and done by a central randomisation by computer.</concealment>
    <sequence>Randomisation is via Interactive Web Response System</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>25/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>210</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2010</postcode>
    <postcode>2522</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Marine Biotechnology Australia Pty Limited</primarysponsorname>
    <primarysponsoraddress>15 Maxwell Road, Hobart, Tasmania, 7000 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Marine Biotechnology Australia Pty Limited</fundingname>
      <fundingaddress>15 Maxwell Road, Hobart, Tasmania, 7000 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novotech (Australia) Pty Limited</othercollaboratorname>
      <othercollaboratoraddress>235 Pyrmont Street, Pyrmont NSW 2009</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Herpes labialis (cold sores) caused by herpes simplex virus type 1 (HSV-1) is a common condition affecting millions of people worldwide. The pathogenesis of the disease suggests that brief and early immunogenic therapy may be a logical approach.
Abalone Haemocyanin (AH) derived from live abalone.  The literature and clinical data generated by the sponsor of this study, indicate that AH has the potential for prophylaxis and therapeutic treatment of all stages of oral herpes.
The proposed study is to look at the safety and effectiveness of topical  AH for 5 days compared with placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>229 Greenhill Road, Dulwich SA 5065</ethicaddress>
      <ethicapprovaldate>16/06/2011</ethicapprovaldate>
      <hrec>2011-05-262</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alek Safarian</name>
      <address>Novotech (Australia) Pty Limited
Level 3, 235 Pyrmont St
Pyrmont NSW 2009
Australia</address>
      <phone>+ 612 8569 1400</phone>
      <fax>+ 612 8569 1498</fax>
      <email>alek.safarian@novotech-cro.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Adrian Cuthbertson</name>
      <address>Marine Biotechnology Australia Pty Limited
15 Maxwells Road
Hobart, Tasmania 7000
Australia</address>
      <phone>+61 (0) 3 6248 5739</phone>
      <fax>+61 (0) 3 6248 5740</fax>
      <email>acuthbertson@bigpond.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Serena King</name>
      <address>Novotech (Australia) Pty Limited
Level 3, 235 Pyrmont St
Pyrmont NSW 2009
Australia</address>
      <phone>+ 612 8569 1400</phone>
      <fax>+ 612 8569 1498</fax>
      <email>serena.king@novotech-cro.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>